Literature DB >> 17611417

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

Judith F Smith1, Michelle Brownlow, Martha Brown, Rose Kowalski, Mark T Esser, Wanda Ruiz, Eliav Barr, Darron R Brown, Janine T Bryan.   

Abstract

Human papillomavirus (HPV) types 6, 11, 16 and 18 L1 virus-like particles (VLPs) have been used to generate the prophylactic quadrivalent vaccine, Gardasil. There is a high degree of L1 homology between HPV types and it is likely that there is a substantial degree of surface exposed viral epitope similarity. An investigation of vaccine-induced antibody binding and neutralization was undertaken focusing on A7 species members, HPV 18 and 45. Polyclonal sera from Gardasil recipients and from HPV 18 L1 VLP recipients were evaluated. Vaccine-induced antibodies were found to cross-neutralize HPV 45 pseudovirions (PsV) in vitro. Examination of a panel of monoclonal antibodies made against L1 VLPs revealed the presence of conformational, neutralizing epitopes on the surface of VLPs that may be shared between HPV 18 and HPV 45. These data demonstrate that Gardasil(r) immunization induces antibodies capable of neutralizing HPV 18 PsV and HPV 45 PsV in vitro.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611417     DOI: 10.4161/hv.3.4.4058

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  47 in total

1.  Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Authors:  Subhashini Jagu; Kihyuck Kwak; Robert L Garcea; Richard B S Roden
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 2.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

3.  [Nobel price for vaccination against cervical cancer: current data and guidelines].

Authors:  H M Hepburn; A M Kaufmann
Journal:  Internist (Berl)       Date:  2009-05       Impact factor: 0.743

4.  Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.

Authors:  Ebenezer Tumban; Pavan Muttil; Carolina Andrea A Escobar; Julianne Peabody; Denis Wafula; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2015-05-21       Impact factor: 3.641

5.  Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females.

Authors:  Tao Haskins-Coulter; Jo Southern; Nick Andrews; Elizabeth Miller
Journal:  Hum Vaccin Immunother       Date:  2017-03-20       Impact factor: 3.452

6.  Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

Authors:  John T Schiller; Douglas R Lowy
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

Review 7.  The role of human papillomavirus in oral squamous cell carcinoma: myth and reality.

Authors:  Katinka Kansy; Oliver Thiele; Kolja Freier
Journal:  Oral Maxillofac Surg       Date:  2012-12-16

8.  Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain.

Authors:  Pablo Conesa-Zamora; Sebastián Ortiz-Reina; Joaquín Moya-Biosca; Asunción Doménech-Peris; Francisco Javier Orantes-Casado; Miguel Pérez-Guillermo; Marcos Egea-Cortines
Journal:  BMC Infect Dis       Date:  2009-08-10       Impact factor: 3.090

9.  Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58.

Authors:  Martha J Brown; Hanna Seitz; Victoria Towne; Martin Müller; Adam C Finnefrock
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

10.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.